API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012

Particulars Quarter Ended Financial Year Ended
Sr. 31st Mar 2012 31st Dec 2011 31st Mar 11 31s Mar 2012 31st Mar 2011
No. (Audited) (Audited) (Audited) (Audited) (Audited)
1 Income from Operations





(a) Gross Sales / Income from Operations 21,165 16,394 15,102 69,918 52,301

Less : Excise Duty & Sales Tax 1,242 885 767 3,992 2,659

(a) Net Sales / Income from Operations 19,923 15,509 14,335 65,926 49,642

(Net Of Excise Duty & Sales Tax)





(b) Other Operating Income 590 3 1 610 8

Total income form operations (net) 20,513 15,512 14,336 66,536 49,650
2 Expenditure





(a). Cost of materials consumed 9,960 8,660 7,985 38,414 27,300

(b). Purchase of stock-in-trade 2,480 1,669 1,849 7,336 8,421

(c). Changes in inventories of finished goods, 1,884 353 352 (92) (1,618)

work-in-progress and stock-in-trade





(d). Employee benefits expense 762 523 476 2,483 1,787

(e). Depreciation and amortisation expense 629 468 474 2,422 1,774

(f). Other expenses 2,789 2,591 2,057 10,368 7,490

Total expenses 18,504 14,264 13,193 60,931 45,155
3 Profit from Operations before Other Income, finance costs and exceptional items (1-2)





2,009 1,248 1,143 5,605 4,495
4 Other Income - - - - -
5 Profit from ordinary activities before finance cost and exceptional items (3+4) 2,009 1,248 1,143 5,605 4,495






6 Finance costs (interest) 697 574 409 2,267 1,348
7 Profit from ordinary activities after finance cost  but before Exceptional Items (5+6)




1,312 674 734 3,338 3,147
8 Exceptional Items 116 - - 116 -
9 Profit from Ordinary Activities before Tax (7+8) 1,195 674 734 3,222 3,147
10 Tax Expenses  (Includes) 454 193 105 976 900

Provision for Taxation 390 118 64 800 650

Provision for Deferred Taxation 64 74 41 176 250
11 Net profit from ordinary Activities after Tax 741 481 629 2,246 2,247
12 Paid-up Equity Share Capital of `10/- each. 1,211 1,211 1,211 1,211 1,211
13 . Reserves & Surplus (excluding revaluation reserves) - - - 16,437 14,441
15 Earning per share(of Rs. 10/- each) (not annualised)











(a) Basic & Diluted 6.11 3.97 5.19 17.84 18.56







 

PART II (` in Lakhs )
A PARTICULARS OF SHAREHOLDING




1 Public shareholding





-Number of Shares 5,379,245 5,469,811 5,569,613 5,379,245 5,569,613

-Percentage of Total Shareholding 44.43 45.17 46.00 44.43 46.00
2 Promoters & Promoter Group shareholding





a) Pledged/Encumbered





- Number of Shares Nil Nil Nil Nil Nil

-Percentage of shares( as a % of the Nil Nil Nil Nil Nil

total shareholding of promoter and promoter group)





-Percentage of shares( as a % of the Nil Nil Nil Nil Nil

total Share capital of the company)





b) Non-encumbered





- Number of Shares 6,729,305 6,638,739 6,538,937 6,729,305 6,538,937

-Percentage of shares( as a % of the total Shareholding 100 100 100 100 100

of promoter and promoter group)





-Percentage of shares( as a % of the total 55.57 54.83 54.00 55.57 54.00

Share capital of the company)




B INVESTOR COMPLAINTS
Qtr ended 31st March, 2012



Pending at the beginning of the quarter
0



Received during the quarter
3



Disposed of during the quarter
3



Remaining unresolved at the end of the quarter
0


 

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2012
(Rs. in Lacs)
Particulars For the year ended
31/03/2012 31/03/2011
A EQUITY AND LIABILITIES
1 Shareholder' funds
(a) Share Capital 1,211 1,211
(b) Reserves and surplus 6,437 14,441
2 Non-current liabilities
(a) Long - term borrowings 6,692 7,434
(b) Deferred tax liabilities (net) 2,447 2,230
(c) Other long - term liabilities 771 757
(d)Long - term provisions - -
Sub - total - Non - current liabilities 9,911 10,421
3 Current liabilities
(a)Short - term borrowings 20,557 14,723
(b) Trade payables 9,379 7,736
(c) Other current liabilities 2,866 2,416
(d) Short - term provisions 902 641
Sub - total -  current liabilities 33,703 25,517
TOTAL- EQUITY AND LIABILITIES 61,262 51,589
B ASSETS
1 Non-current assets
(a) Fixed assets 27,653 23,458
(b) Non - current investments 692 2,461
(c) Long - term loans and advances 227 863
Sub - total - Non - current assets 28,571 26,782
2 Current assets
(a) Inventories 9,791 8,316
(b) Trade receivables 18,060 12,583
(c) Cash and cash equivalents 494 359
(d) Short - term loans and advances 2,715 2,276
(e)Other non - current assets 1,630 1,273
Sub - total -  current assets 32,691 24,807
TOTAL - ASSETS 61,262 51,589
Notes :
1. The above merged results for the year ended 31st March, 2012 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th July, 2012 consequent upon amalgamation of Suyash Laboratories Limited  (“Transferor Company”) (being wholly owned subsidiary of Aarti Drugs Limited)  with Aarti Drugs Limited(Transferee Company) having become operative from 01.04.2011 (Appointed Date).
2. The Board of Directors has already recommended a Final Dividend of Rs. 3.00/- per Equity Share for the year 2011-12 to the members of the Company.
3. Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
4. Figures for the previous period have been regrouped or rearranged wherever necessary.
5. Previous year's figures are of Aarti Drugs Limited stand alone and hence are not comparable.
For and on behalf of the Board
Place : Mumbai For AARTI DRUGS LIMITED
Date: 9th July, 2012
HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech